Survive Or Fall: Korean Strategy In Changing Big Pharma Environment
Focus On Oncology, Early Stage Assets
Executive Summary
As the global economy remains in a slump, even big pharmas such as Novartis and Pfizer are cutting costs. So how should Korean biopharmas adapt to such an environment and move ahead? Korea Drug Development Fund CEO H. Samuel Muk provides some ideas on how domestic players can survive in this new global reality.